相似文献
1
Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA.《新冠疫苗的科学与循证审查及批准：对美国食品药品监督管理局的支持声明》
J Clin Pharmacol. 2021 Mar;61(3):277-279. doi: 10.1002/jcph.1794. Epub 2021 Jan 27.
2
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.在初始候选疫苗获得紧急使用授权或批准上市后评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗
JAMA. 2021 Jan 19;325(3):221-222. doi: 10.1001/jama.2020.25127.
3
FDA authorizes Pfizer-BioNTech COVID-19 vaccine.美国食品药品监督管理局批准辉瑞-生物科技公司的新冠病毒疫苗。
Med Lett Drugs Ther. 2021 Jan 11;63(1615):1-2.
4
US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.美国食品药品监督管理局在为一种新冠疫苗发布紧急使用授权后，对安慰剂对照试验采取的不稳定做法。
Vaccine. 2021 Feb 22;39(8):1180-1182. doi: 10.1016/j.vaccine.2021.01.050. Epub 2021 Jan 20.
5
Being fair to participants in placebo-controlled COVID-19 vaccine trials.公平对待参与新冠病毒疫苗安慰剂对照试验的受试者。
Nat Med. 2021 Jun;27(6):938. doi: 10.1038/s41591-021-01338-1.
6
Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.新冠疫苗的紧急使用授权——安全性和有效性随访考量
N Engl J Med. 2020 Nov 5;383(19):e107. doi: 10.1056/NEJMp2031373. Epub 2020 Oct 16.
7
COVID-19 Vaccine Considerations during Pregnancy and Lactation.孕期及哺乳期的新冠疫苗接种考量
Am J Perinatol. 2021 May;38(6):523-528. doi: 10.1055/s-0041-1726390. Epub 2021 May 1.
8
FDA authorizes Johnson & Johnson COVID-19 vaccine.美国食品药品监督管理局批准强生公司的新冠疫苗。
Med Lett Drugs Ther. 2021 Mar 22;63(1620):41-42.
9
FDA authorizes Moderna COVID-19 vaccine.美国食品药品监督管理局批准莫德纳新冠疫苗。
Med Lett Drugs Ther. 2021 Jan 25;63(1616):9-10.
10
The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines.评估新冠疫苗价值的新方法需求
Am J Public Health. 2021 Feb;111(2):205-208. doi: 10.2105/AJPH.2020.306066.
引用本文的文献
1
Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients.埃及患者中影响2019冠状病毒病感染临床结局及疫苗安全性的因素评估
BMC Infect Dis. 2025 Mar 19;25(1):384. doi: 10.1186/s12879-024-10362-8.
2
Coronavirus Disease 2019 Frequency After CoronaVac Vaccine: Ascovid Study.科兴疫苗接种后2019冠状病毒病发病率：Ascovid研究
Thorac Res Pract. 2023 Jan;24(1):29-33. doi: 10.5152/ThoracResPract.2022.22045.
3
Assessing public knowledge, attitudes and determinants of third COVID-19 vaccine booster dose acceptance: current scenario and future perspectives.评估公众对第三剂新冠疫苗加强针的认知、态度及接受度的决定因素：当前情况与未来展望
J Pharm Policy Pract. 2022 Mar 28;15(1):26. doi: 10.1186/s40545-022-00422-2.
4
Acceptance of COVID-19 Vaccination in the Elderly: A Cross-Sectional Study in Southern Italy.意大利南部老年人对新冠疫苗的接受情况：一项横断面研究
Vaccines (Basel). 2021 Oct 21;9(11):1222. doi: 10.3390/vaccines9111222.
5
Knowledge and Acceptance of COVID-19 Vaccination among Undergraduate Students from Central and Southern Italy.意大利中部和南部大学生对新冠疫苗的认知与接受情况
Vaccines (Basel). 2021 Jun 10;9(6):638. doi: 10.3390/vaccines9060638.
6
An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的最新综述及大流行时期有效疫苗接种计划的重要性
Vaccines (Basel). 2021 Apr 27;9(5):433. doi: 10.3390/vaccines9050433.
本文引用的文献
1
Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust.评估与部署新冠疫苗——透明度、科学诚信及公众信任的重要性
N Engl J Med. 2020 Oct 29;383(18):1703-1705. doi: 10.1056/NEJMp2026393. Epub 2020 Sep 23.
2
Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach.开发安全有效的新冠疫苗——“极速行动”计划的策略与方法。
N Engl J Med. 2020 Oct 29;383(18):1701-1703. doi: 10.1056/NEJMp2027405. Epub 2020 Aug 26.
3
Unwavering Regulatory Safeguards for COVID-19 Vaccines.对新冠疫苗坚定不移的监管保障措施。
JAMA. 2020 Sep 8;324(10):931-932. doi: 10.1001/jama.2020.15725.
4
FDA Approval and Regulation of Pharmaceuticals, 1983-2018.FDA 对药品的批准与监管，1983-2018 年。
JAMA. 2020 Jan 14;323(2):164-176. doi: 10.1001/jama.2019.20288.
5
Regulatory review of novel therapeutics--comparison of three regulatory agencies.新型治疗药物的监管审查——三个监管机构的比较。
N Engl J Med. 2012 Jun 14;366(24):2284-93. doi: 10.1056/NEJMsa1200223. Epub 2012 May 16.
Zotero 插件